| 1 | English French Notes Complete/Exclude
|
|---|
| 2 | DIAGNOSITC INFORMATION
|
|---|
| 3 | HISTOLOGY (ICD-O)
|
|---|
| 4 | DIFFERENTIATION/GRADE
|
|---|
| 5 | GLEASON'S SCORE
|
|---|
| 6 | DIAGNOSTIC INFORMATION
|
|---|
| 7 | METHOD OF DIAGNOSIS:
|
|---|
| 8 | 600 CLINICAL DX WITH BONE LESION
|
|---|
| 9 | 601 CLINICAL DX BY RECTAL EXAM..
|
|---|
| 10 | 603 INCIDENTAL FINDING IN TURP..
|
|---|
| 11 | 604 NEEDLE ASPIRATION BIOPSY....
|
|---|
| 12 | 605 NEEDLE BIOPSY, NOS..........
|
|---|
| 13 | 606 PERINEAL BIOPSY.............
|
|---|
| 14 | 607 TRANSRECTAL BIOPSY..........
|
|---|
| 15 | 608 TRUS GUIDED BIOPSY..........
|
|---|
| 16 | 609 TRANSURETHRAL RESECTION, NOS
|
|---|
| 17 | DATE OF INITIAL DIAGNOSIS.....:
|
|---|
| 18 | 611 BONE MARROW ASPIRATION......
|
|---|
| 19 | 612 BONE SCAN...................
|
|---|
| 20 | 615 CT SCAN OF PRIMARY SITE.....
|
|---|
| 21 | 617 LIVER SCAN..................
|
|---|
| 22 | 619 PELVIC LYMPH NODE DISSECTION
|
|---|
| 23 | TABLE III - STAGE OF DISEASE
|
|---|
| 24 | 38 AJCC STAGE.....
|
|---|
| 25 | 19 CLINICAL STAGED BY..
|
|---|
| 26 | 88 AJCC STAGE.....
|
|---|
| 27 | 89 PATHOLOGIC STAGED BY
|
|---|
| 28 | RADIATON THERAPY
|
|---|
| 29 | TYPE OF SURGERY................:
|
|---|
| 30 | DATE OF SURGERY................:
|
|---|
| 31 | REASON FOR NO SURGERY..........:
|
|---|
| 32 | SURGICAL APPROACH..............:
|
|---|
| 33 | 624 RESEARCH PROTOCOL..............
|
|---|
| 34 | 625 RADIATION THERAPY..............
|
|---|
| 35 | DATE RADIATION THERAPY BEGAN...:
|
|---|
| 36 | 626 INTERSTITIAL RADIATION.........
|
|---|
| 37 | INTERSTITIAL RADIATION ADMINISTERED:
|
|---|
| 38 | 631 OTHER INTERSTITIAL, NOS......
|
|---|
| 39 | 632 EXTERNAL RADIATION.............
|
|---|
| 40 | EXTERNAL RADIATION ADMINISTERED:
|
|---|
| 41 | 633 PROSTATE REGION ONLY.........
|
|---|
| 42 | 634 PROSTATE/PELVIC NODES........
|
|---|
| 43 | 635 PARA-AORTIC NODES............
|
|---|
| 44 | 636 DISTANT METASTATIC SITES.....
|
|---|
| 45 | 637 OTHER EXTERNAL SITES, NOS....
|
|---|
| 46 | TOTAL RAD DOSE:
|
|---|
| 47 | 639 PELVIC NODES.................
|
|---|
| 48 | 640 PARA-AORTIC NODES............
|
|---|
| 49 | 641 RESEARCH PROTOCOL..............
|
|---|
| 50 | HORMONE THERAPY:
|
|---|
| 51 | 642 HORMONE THERAPY................
|
|---|
| 52 | DATE HORMONE THERAPY BEGAN.....:
|
|---|
| 53 | HORMONES ADMINISTERED:
|
|---|
| 54 | 645 PROGESTATIONAL AGENTS........
|
|---|
| 55 | 646 LUTEINIZING HORMONE-RELEASING
|
|---|
| 56 | METHODS USED TO DIAGNOSE FIRST RECURRENCE
|
|---|
| 57 | 71TYPE OF FIRST RECURRENCE........
|
|---|
| 58 | 70DATE OF FIRST RECURRENCE........
|
|---|
| 59 | METHODS USED TO DIAGNOSE FIRST RECURRENCE:
|
|---|
| 60 | 650 BONE SCAN.....................
|
|---|
| 61 | 652 RECTAL EXAM WITH NEEDLE BIOSPY
|
|---|
| 62 | 653 TUMOR MARKER ELEVATION........
|
|---|
| 63 | 654 WEIGHT LOSS...................
|
|---|
| 64 | TABLE VI - SUBSEQUENT TREATMENT
|
|---|
| 65 | 656REASON FOR SECOND COURSE OF THERAPY
|
|---|
| 66 | SUBSEQUENT SURGERY #
|
|---|
| 67 | TYPE OF SURGERY....................:
|
|---|
| 68 | DATE OF SURGERY....................:
|
|---|
| 69 | SUBSEQUENT RADIATION THERAPY #
|
|---|
| 70 | 16RADIATION THERAPY..................
|
|---|
| 71 | DATE RADIATON THERAPY BEGAN........:
|
|---|
| 72 | 4INTERSTITIAL RADIATION.............
|
|---|
| 73 | 9 OTHER INTERSTITIAL, NOS........
|
|---|
| 74 | 10EXTERNAL RADIATION.................
|
|---|
| 75 | 11 PROSTATE REGION ONLY...........
|
|---|
| 76 | 12 PROSTATE & PELVIC NODES........
|
|---|
| 77 | 13 PARA-AORTIC NODES..............
|
|---|
| 78 | 14 DISTANT METASTATIC SITES.......
|
|---|
| 79 | 15 OTHER EXTERNAL, NOS............
|
|---|
| 80 | 18 PELVIC NODES...................
|
|---|
| 81 | 19 PARA-AORTIC NODES..............
|
|---|
| 82 | SUBSEQUENT CHEMOTHERAPY #
|
|---|
| 83 | DATE CHEMOTHERAPY BEGAN............:
|
|---|
| 84 | DRUGS ADMINISTERED:
|
|---|
| 85 | SUBSEQUENT HORMONE THERAPY #
|
|---|
| 86 | 26HORMONE THERAPY....................
|
|---|
| 87 | DATE HORMONE THERAPY BEGAN.........:
|
|---|
| 88 | 29 PROGESTATIONAL AGENTS..........
|
|---|
| 89 | 30 LUTEINIZING HORMONE-RELEASING..
|
|---|
| 90 | ACCESSION/SEQUENCE NUMBER..........:
|
|---|
| 91 | CLASS OF CASE......................:
|
|---|
| 92 | ZIP CODE...........................:
|
|---|
| 93 | BIRTHDATE..........................:
|
|---|
| 94 | RACE...............................:
|
|---|
| 95 | PRIMARY PAYER AT DIAGNOSIS.........:
|
|---|
| 96 | DATE OF ADMISSION..................:
|
|---|
| 97 | DATE OF DISCHARGE..................:
|
|---|
| 98 | CLINICAL DX WITH BONE LESION.....:
|
|---|
| 99 | CLINICAL DX BY RECTAL EXAM.......:
|
|---|
| 100 | INCIDENTAL FINDING IN TURP.......:
|
|---|
| 101 | NEEDLE ASPIRATION BIOPSY.........:
|
|---|
| 102 | NEEDLE BIOPSY, NOS...............:
|
|---|
| 103 | PERINEAL BIOPSY..................:
|
|---|
| 104 | TRANSRECTAL BIOPSY...............:
|
|---|
| 105 | TRUS GUIDED BIOPSY...............:
|
|---|
| 106 | TRANSURETHRAL RESECTION, NOS.....:
|
|---|
| 107 | DATE OF INITIAL DIAGNOSIS..........:
|
|---|
| 108 | BONE MARROW ASPIRATION...........:
|
|---|
| 109 | BONE SCAN........................:
|
|---|
| 110 | CT SCAN OF PRIMARY SITE..........:
|
|---|
| 111 | LIVER SCAN.......................:
|
|---|
| 112 | PELVIC LYMPH NODE DISSECTION.....:
|
|---|
| 113 | HISTOLOGY (ICD-O)..................:
|
|---|
| 114 | DIFFERENTIATION/GRADE..............:
|
|---|
| 115 | GLEASON'S SCORE....................:
|
|---|
| 116 | AJCC STAGE....................:
|
|---|
| 117 | CLINICAL STAGE..................:
|
|---|
| 118 | PATHOLOGIC STAGE.................:
|
|---|
| 119 | Print Prostate PCE Data.
|
|---|
| 120 | PCE Studies of Cancer of the Prostate
|
|---|
| 121 | REASON FOR NO SURGERY.............:
|
|---|
| 122 | SURGICAL APPROACH.................:
|
|---|
| 123 | RESEARCH PROTOCOL.................:
|
|---|
| 124 | DATE RADIATION THERAPY BEGAN......:
|
|---|
| 125 | INTERSTITIAL RADIATION............:
|
|---|
| 126 | OTHER INTERSTITIAL, NOS.........:
|
|---|
| 127 | EXTERNAL RADIATION................:
|
|---|
| 128 | PROSTATE REGION ONLY............:
|
|---|
| 129 | PROSTATE/PELVIC NODES...........:
|
|---|
| 130 | PARA-AORTIC NODES...............:
|
|---|
| 131 | DISTANT METASTATIC SITES........:
|
|---|
| 132 | OTHER EXTERNAL SITES, NOS.......:
|
|---|
| 133 | PELVIC NODES....................:
|
|---|
| 134 | RESEARCH PROTOCOL...............:
|
|---|
| 135 | HORMONE THERAPY...................:
|
|---|
| 136 | DATE HORMONE THERAPY BEGAN........:
|
|---|
| 137 | PROGESTATIONAL AGENTS...........:
|
|---|
| 138 | LUTEINIZING HORMONE-RELEASING...:
|
|---|
| 139 | BONE SCAN.........................:
|
|---|
| 140 | RECTAL EXAM WITH NEEDLE BIOSPY....:
|
|---|
| 141 | TUMOR MARKER ELEVATION............:
|
|---|
| 142 | WEIGHT LOSS.......................:
|
|---|
| 143 | REASON FOR SECOND COURSE OF THERAPY:
|
|---|
| 144 | RADIATION THERAPY..................:
|
|---|
| 145 | INTERSTITIAL RADIATION.............:
|
|---|
| 146 | OTHER INTERSTITIAL, NOS........:
|
|---|
| 147 | EXTERNAL RADIATION.................:
|
|---|
| 148 | PROSTATE REGION ONLY...........:
|
|---|
| 149 | PROSTATE & PELVIC NODES........:
|
|---|
| 150 | PARA-AORTIC NODES..............:
|
|---|
| 151 | DISTANT METASTATIC SITES.......:
|
|---|
| 152 | OTHER EXTERNAL, NOS............:
|
|---|
| 153 | PELVIC NODES...................:
|
|---|
| 154 | CHEMOTHERAPY.......................:
|
|---|
| 155 | HORMONE THERAPY....................:
|
|---|
| 156 | PROGESTATIONAL AGENTS..........:
|
|---|
| 157 | LUTEINIZING HORMONE-RELEASING..:
|
|---|
| 158 | DATE OF LAST CONTACT OR DEATH.....:
|
|---|
| 159 | VITAL STATUS......................:
|
|---|
| 160 | CANCER STATUS.....................:
|
|---|
| 161 | AUTOPSY...........................:
|
|---|
| 162 | COMPLETED BY......................:
|
|---|
| 163 | REVIEWED BY CANCER COMMITTEE......:
|
|---|
| 164 | Checking for any duplicates in ICDO MORHOLOGY (#164.1) file...
|
|---|
| 165 | MARGINAL ZONE LYMPHOMA, NOS IN
|
|---|
| 166 | MARGINAL ZONE LYMPHOMA, NOS
|
|---|
| 167 | Converting file #165.5 pointers...
|
|---|
| 168 | CANNOT CONVERT POINTER IN ENTRY NUMBER:
|
|---|
| 169 | Converting file #160 pointers...
|
|---|
| 170 | Converting file #169.1 pointers...
|
|---|
| 171 | Converting file #164.1 pointers...
|
|---|
| 172 | Converting file #164.2 pointers...
|
|---|
| 173 | .01///MARGINAL ZONE LYMPHOMA, NOS IN SITU
|
|---|
| 174 | .01///MARGINAL ZONE LYMPHOMA, NOS
|
|---|
| 175 | Tumor Size...................:
|
|---|
| 176 | Lymph Node...................:
|
|---|
| 177 | Regional Lymph Nodes Examined:
|
|---|
| 178 | Regional Lymph Nodes Positive:
|
|---|
| 179 | SEER Summary Stage 2000......:
|
|---|
| 180 | Site of Distant Metastasis #1:
|
|---|
| 181 | Site of Distant Metastasis #2:
|
|---|
| 182 | Site of Distant Metastasis #3:
|
|---|
| 183 | Clinical Staging
|
|---|
| 184 | TNM edition:
|
|---|
| 185 | Pathologic Staging
|
|---|
| 186 | TNM........:
|
|---|
| 187 | Stage Group:
|
|---|
| 188 | Stage Group:
|
|---|
| 189 | Staged By..:
|
|---|
| 190 | Staged By..:
|
|---|
| 191 | Lymphatic Vessel Invasion (L):
|
|---|
| 192 | Venous Invasion (V)..........:
|
|---|
| 193 | Other Stage..................:
|
|---|
| 194 | Restaging primaries with an ICD0-TOPOGRAPHY of C21.0, C53.0 or C31.8 and a
|
|---|
| 195 | DATE DX > 12/31/91.
|
|---|
| 196 | Restaging
|
|---|
| 197 | primary for patient
|
|---|
| 198 | Reindexing ATX cross-reference...
|
|---|
| 199 | .01 USUAL OCCUPATION...........
|
|---|
| 200 | 3 USUAL INDUSTRY.............
|
|---|
| 201 | 38 TOBACCO HISTORY............
|
|---|
| 202 | .01 TYPE OF TOBACCO USER.......
|
|---|
| 203 | 2 YR QUIT TOBACCO USE........
|
|---|
| 204 | 39 ALCOHOL HISTORY............
|
|---|
| 205 | .01 TYPE OF ALCOHOL USER.......
|
|---|
| 206 | 1 YRS OF ALCOHOL USE.........
|
|---|
| 207 | 2 DRINKS PER DAY.............
|
|---|
| 208 | 3 YR QUIT DRINKING...........
|
|---|
| 209 | 43 FAMILY HISTORY OF CANCER...
|
|---|
| 210 | .01 FAMILY MEMBER WITH CANCER..
|
|---|
| 211 | **NOTE** CLASS OF CASE = 4 (Dx/1st tx before ref date)
|
|---|
| 212 | The @FAC (at this facility) fields will be stuffed to
|
|---|
| 213 | match the primary treatment fields.
|
|---|
| 214 | 0 (Dx here, 1st tx ew)
|
|---|
| 215 | 3 (Dx ew, 1st tx ew)
|
|---|
| 216 | 6 (Dx/1st tx in MD office)
|
|---|
| 217 | **NOTE** CLASS OF CASE =
|
|---|
| 218 | appropriate value indicating that no treatment was given
|
|---|
| 219 | at this facility.
|
|---|
| 220 | SURGICAL DIAGNOSTIC AND STAGING PROCEDURES
|
|---|
| 221 | Surgical Dx/Staging Proc.....:
|
|---|
| 222 | Surg Dx/Staging Proc @fac....:
|
|---|
| 223 | SURGICAL PROCEDURES (ROADS)
|
|---|
| 224 | Pre-2003 cases require the following ROADS surgery items to be coded:
|
|---|
| 225 | Surgery of primary.........(R):
|
|---|
| 226 | Surgical Approach..........(R):
|
|---|
| 227 | Surgery of primary @fac....(R):
|
|---|
| 228 | Scope of ln surgery........(R):
|
|---|
| 229 | Number of LN removed...... (R):
|
|---|
| 230 | Scope of ln surgery @fac...(R):
|
|---|
| 231 | Number of LN removed @fac..(R):
|
|---|
| 232 | Surg proc/other site.......(R):
|
|---|
| 233 | Surg proc/other site @fac..(R):
|
|---|
| 234 | SURGICAL PROCEDURES (FORDS)
|
|---|
| 235 | Date of 1st Surgical Procedure:
|
|---|
| 236 | Surgery of primary.........(F):
|
|---|
| 237 | Surgery of primary @fac....(F):
|
|---|
| 238 | Surgical margins..............:
|
|---|
| 239 | Scope of ln surgery........(F):
|
|---|
| 240 | Scope of ln surgery @fac...(F):
|
|---|
| 241 | Surg proc/other site.......(F):
|
|---|
| 242 | Surg proc/other site @fac..(F):
|
|---|
| 243 | Date of surgical discharge....:
|
|---|
| 244 | Reason for no surgery.........:
|
|---|
| 245 | Date radiation started........:
|
|---|
| 246 | Location of radiation tx......:
|
|---|
| 247 | Radiation treatment volume....:
|
|---|
| 248 | Regional treatment modality...:
|
|---|
| 249 | Regional dose:cGy.............:
|
|---|
| 250 | Boost treatment modality......:
|
|---|
| 251 | Boost dose:cGy................:
|
|---|
| 252 | Number of txs to this volume..:
|
|---|
| 253 | Radiation/surgery sequence....:
|
|---|
| 254 | Date radiation ended..........:
|
|---|
| 255 | Reason for no radiation.......:
|
|---|
| 256 | SYSTEMIC THERAPY
|
|---|
| 257 | Date systemic therapy started.:
|
|---|
| 258 | Hormone therapy...............:
|
|---|
| 259 | Hormone therapy @fac..........:
|
|---|
| 260 | Hema Trans/Endocrine Proc.....:
|
|---|
| 261 | OTHER TREATMENT
|
|---|
| 262 | Other treatment...............:
|
|---|
| 263 | Other treatment @fac..........:
|
|---|
| 264 | PALLIATIVE PROCEDURE/PROTOCOL PARTICIPATION
|
|---|
| 265 | Pain assessment...............:
|
|---|
| 266 | Palliative procedure..........:
|
|---|
| 267 | Palliative procedure @fac.....:
|
|---|
| 268 | Protocol eligibility status...:
|
|---|
| 269 | Protocol participation........:
|
|---|
| 270 | Year put on protocol..........:
|
|---|
| 271 | Histology code is incompatible.
|
|---|
| 272 | NOTE: Papillary or Follicular
|
|---|
| 273 | IS PU00
|
|---|
| 274 | IS PD00
|
|---|
| 275 | The Accession Year is not 1996.
|
|---|
| 276 | The Class of Case code is not 1 or 2.
|
|---|
| 277 | Skin sites are only allowed for patients with dermatofibrosarcoma.
|
|---|
| 278 | 8:Print Soft Tissue Sarcoma PCE
|
|---|
| 279 | Patient Care Evaluation Study of Soft Tissue Sarcoma
|
|---|
| 280 | FAMILY HISTORY OF SOFT TISSUE SARCOMA
|
|---|
| 281 | 500FAMILY HISTORY OF SOFT TISSUE SARCOMA
|
|---|
| 282 | 501PERSONAL HISTORY OF ANY CANCER.......
|
|---|
| 283 | HISTOLOGIC WORKUP
|
|---|
| 284 | OUTSIDE CONFIRMATION OF BIOPSY
|
|---|
| 285 | ADDNL GRADE CODING SYSTEM
|
|---|
| 286 | VALUE OF ADDNL CODING SYSTEM
|
|---|
| 287 | TABLE II- INITIAL DIAGNOSIS/CANCER IDENTIFICATION
|
|---|
| 288 | CLASS OF CLASS................:
|
|---|
| 289 | 502 ANGIOGRAM OF PRIMARY........
|
|---|
| 290 | 503 BONE MARROW ASPIRATE/BIOPSY.
|
|---|
| 291 | 504 BONE SCAN...................
|
|---|
| 292 | 506 CT SCAN OF CHEST............
|
|---|
| 293 | 507 CT SCAN OF PRIMARY..........
|
|---|
| 294 | 508 LIVER FUNCTION STUDIES......
|
|---|
| 295 | 510 MRI OF PRIMARY..............
|
|---|
| 296 | 511 MRI OF OTHER................
|
|---|
| 297 | HISTOLOGIC WORKUP:
|
|---|
| 298 | 515 ELECTRON MICROSCOPY.........
|
|---|
| 299 | 329 FLOW CYTOMETRY..............
|
|---|
| 300 | 517 IN SITU HYBRIDIZATION.......
|
|---|
| 301 | BIOPSIES:
|
|---|
| 302 | TYPE HISTOLOGY/BEHAVIOR/GRADE
|
|---|
| 303 | #################### #################### ####################
|
|---|
| 304 | #################### #################### ####################
|
|---|
| 305 | #################### #################### ####################
|
|---|
| 306 | #################### #################### ####################
|
|---|
| 307 | #################### #################### ####################
|
|---|
